Norgine Expands Its Hepatology Portfolio with Exclusive Licensing Agreement Norgine enhances its portfolio of hepatology products through a significant licensing agreement with Vir Biotechnology, focusing on hepatitis delta treatment.

Norgine Expands Its Hepatology Portfolio with Exclusive Licensing Agreement #None #Norgine #Vir_Biotechnology #Hepatitis_Delta

Norgine Expands Hepatology Portfolio with Exclusive Licensing Agreement for Innovative Therapy Norgine has announced an exclusive agreement to market a new therapy for chronic hepatitis delta, reinforcing its commitment to innovative patient care.

Norgine Expands Hepatology Portfolio with Exclusive Licensing Agreement for Innovative Therapy #United_Kingdom #Norgine #Uxbridge #Vir_Biotechnology #Hepatitis_Delta

Norgine Expands Specialty Pharmaceutical Portfolio with Licensing Deal with Vir Biotechnology Norgine has secured an exclusive licensing agreement with Vir Biotechnology to commercialize a groundbreaking treatment for chronic hepatitis delta, targeting high unmet medical needs across Europe and Oceania.

Norgine Expands Specialty Pharmaceutical Portfolio with Licensing Deal with Vir Biotechnology #UK #Norgine #Uxbridge #Vir_Biotechnology #Hepatitis_Delta